Safety, efficacy and feasibility of preventive treatment for drug-resistant tuberculosis with moxifloxacin or bedaquiline

Safety, efficacy and feasibility of preventive treatment for drug-resistant tuberculosis with moxifloxacin or bedaquiline

Publication date: Mar 11, 2025

IntroductionRates of drug-resistant tuberculosis (TB) are increasing worldwide. TB preventive treatment (TPT) for contacts of active TB patients is essential to halt infection progression and transmission. While newer TPT regimens for drug-sensitive strains are expanding, optimal treatment for contacts exposed to drug-resistant TB (DR-TB) remains unclear. In 2019-2020, Vladimir City, Russia, introduced moxifloxacin and bedaquiline-based TPT regimens to prevent disease development in contacts exposed to DR-TB. MethodsWe conducted a retrospective cohort study using medical records data that included adult TB contacts, people experiencing homelessness, and persons with HIV who received TPT in Vladimir City, Russia, between 2019 and 2020. Those without TB disease but with indications for TPT were offered one of six regimens, based on drug-susceptible testing results of index patient: Rifapentine/Isoniazid (3HP), Isoniazid (6H), Rifabutin/Isoniazid (3HRb), Rifampicin (4R), Moxifloxacin (4Mfx), or Bedaquiline (3Bdq). Adverse drug reactions (ADRs) were monitored with monthly lab tests and ECGs. ResultsOver 24 months, 403 people started TPT. No life-threatening ADRs or deaths occurred. The lowest ADR rate and significantly higher completion rate was observed in 3Bdq (n=20, 95.2%) compared to 3HP (n=192, 75.9%, Mid-P exact = .03). The rate of TB disease per 1,000 person-years of observation was four times higher in individuals eligible for TPT who did not start it compared to those who initiated TPT. ConclusionTreatment for the prevention of DR-TB, including forms resistant to rifampicin and fluoroquinolones, is feasible, effective and safe. This study introduces a novel paradigm for TB prevention in high-burden DR-TB settings, offering a promising strategy to protect contacts and reduce transmission. Key pointsMoxifloxacin and bedaquiline are safe, effective, and feasible agents for preventive therapy among contacts of individuals with drug-resistant tuberculosis (TB) and can be used as part of the comprehensive search-treat-prevent approach for TB elimination.

PDF

Concepts Keywords
50kg Adrs
Chemotherapy Completion
Nonprofit Contacts
Norway Drug
Https
Individuals
Isoniazid
Medrxiv
Preprint
Preventive
Resistant
Tpt
Treatment
Tuberculosis
Vladimir

Semantics

Type Source Name
disease MESH drug-resistant tuberculosis
drug DRUGBANK Moxifloxacin
drug DRUGBANK Bedaquiline
disease MESH infection
drug DRUGBANK Rifapentine
drug DRUGBANK Isoniazid
drug DRUGBANK Rifabutin
drug DRUGBANK Rifampicin
disease MESH Adverse drug reactions
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Medrysone
disease MESH latent infection
disease IDO intervention
drug DRUGBANK Levofloxacin
drug DRUGBANK Pyrazinamide
disease IDO bactericidal
disease MESH AIDS
disease IDO algorithm
disease IDO symptom
disease IDO assay
disease IDO contact tracing
disease MESH erythema
disease MESH contraindications
disease MESH drug interactions
drug DRUGBANK Etoperidone
disease IDO blood
disease MESH syndrome
drug DRUGBANK Ademetionine
drug DRUGBANK Ethanol
disease MESH latent tuberculosis infection
drug DRUGBANK Coenzyme M
disease MESH cancer
disease MESH relapse
disease MESH allergy
disease MESH high blood pressure
disease MESH pancreatitis
disease MESH psychosis
disease MESH syncope
drug DRUGBANK L-Threonine

Download Document

Leave a Comment

Your email address will not be published. Required fields are marked *